Anat Loewenstein, MD, MHA
Anat Loewenstein, MD, MHA, is Professor and Director, Division of Ophthalmology at the Tel Aviv Medical Center, VP Ambulatory Services at the Tel Aviv Medical Center, Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at Tel Aviv University, and President of the EURETINA.
Dr. Loewenstein’s main field of interest is the investigation of drug administration and toxicity to the retina, early detection of macular degeneration and home monitoring of retinal disease. She has been leading several cutting-edge technologies implemented in large scale clinical trials and in clinical setting, including the home OCT, a first-of-a-its-kind artificial intelligence-enabled algorithm for monitoring retinal diseases, utilizing an OCT device in the patient’s own home, and the development of a technology implementing virtual reality in vitreoretinal surgery in order to replace the standard operating microscope. She also took a pivotal part in the early development of the Port Delivery System – an innovative, FDA approved, intraocular drug delivery system.
She serves on advisory boards of most large pharmaceutical ophthalmological companies, published more than 500 papers in peer reviewed journals, and contributed multiple chapters to ophthalmology textbooks. Dr. Loewenstein serves as the Editor in Chief of the Journal Case Reports in Ophthalmology and is an associate editor of Investigative Ophthalmology & Visual Science Journal, European Journal of Ophthalmology, and of Ophthalmologica. She has many additional national and international roles as a leader in the field of retinal disease, which includes being members of the national council of surgery, the Israeli Academy of medicine, the Academia Ophthalmological Internationalis, and leads mentorship groups of ARVO, EURETINA and programs sponsored by the industry. She leads multiple mentorship programs to young retina specialists including the EURETINA mentorship program and others organized by the industry. Dr. Loewenstein currently serves on the Board of Notal Vision and Pulsenmore, as well as on the Board of ESASO (European school for advanced studies in ophthalmology).